Q1 Earnings Forecast for ESPR Issued By HC Wainwright

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Esperion Therapeutics in a note issued to investors on Tuesday, March 10th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.04) EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at $0.25 EPS and FY2028 earnings at $0.45 EPS.

A number of other research firms also recently issued reports on ESPR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. Needham & Company LLC lifted their price target on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Piper Sandler assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price target for the company. Finally, Wall Street Zen cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.25.

Esperion Therapeutics Price Performance

ESPR opened at $2.47 on Thursday. The company’s 50-day moving average is $3.30 and its 200 day moving average is $3.14. Esperion Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $4.18. The firm has a market capitalization of $590.48 million, a PE ratio of -14.53, a P/E/G ratio of 1.47 and a beta of 1.11.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The firm had revenue of $168.45 million during the quarter, compared to the consensus estimate of $165.12 million.

Insider Buying and Selling

In other Esperion Therapeutics news, CFO Benjamin Halladay sold 7,337 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total value of $26,926.79. Following the transaction, the chief financial officer directly owned 467,525 shares in the company, valued at $1,715,816.75. This represents a 1.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 15,543 shares of company stock worth $55,709 in the last three months. 1.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds have recently made changes to their positions in the business. AIGH Capital Management LLC bought a new position in shares of Esperion Therapeutics during the third quarter valued at about $7,950,000. Two Seas Capital LP grew its position in shares of Esperion Therapeutics by 43.6% in the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock worth $9,800,000 after buying an additional 3,024,104 shares during the last quarter. Royce & Associates LP bought a new position in Esperion Therapeutics in the 3rd quarter worth $6,078,000. Diametric Capital LP boosted its position in Esperion Therapeutics by 57.8% during the 2nd quarter. Diametric Capital LP now owns 678,824 shares of the biopharmaceutical company’s stock valued at $668,000 after acquiring an additional 248,648 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Esperion Therapeutics during the 3rd quarter valued at approximately $476,000. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics News Summary

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Q4 revenue beat — Esperion reported a 144% jump in Q4 revenue to $168.4M, comfortably beating consensus and showing strong top-line growth that supports the company’s commercial traction. ESPR’s Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
• Neutral Sentiment: HC Wainwright retains a Buy rating and provided detailed quarterly estimates for 2026 (Q1: -$0.08, Q2: -$0.05, Q3: -$0.04, Q4: $0.05) — the firm expects the company to reach roughly break-even in FY2026. This keeps upside narrative alive, but the path is mixed near-term. MarketBeat ESPR
• Negative Sentiment: Material downward revisions to longer-term EPS — HC Wainwright cut FY2026 EPS to $0.00 (from $0.58), FY2027 to $0.25 (from $0.81) and FY2028 to $0.45 (from $1.07). Those reductions lower investor expectations for multi-year profitability and likely explain downward pressure on the stock despite the revenue beat. MarketBeat ESPR

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.